Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

The usual treatment

PreclinicalSmall molecule

MMohammad Sadegh Bagheri Baghdasht

The usual treatment is one of 2 small molecule programs targeting Melatonin. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelatoninUnknown status

MelatoninPreclinical

Unknown status

Competition

Competitive Landscape

1 competitor in Melatonin

#DrugCompanyPhaseTrials

Mineral Trioxide Aggregate

JJordan University of Science and Technology

The usual treatment

MMohammad Sadegh Bagheri Baghdasht

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Melatonin1 trial

Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients

Unknown status·MMohammad Sadegh Bagheri Baghdasht·N/A·NCT04409522·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for The usual treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — The usual treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for The usual treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mohammad Sadegh Bagheri Baghdasht company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMohammad Sadegh Bagheri Baghdasht

Related News